FendX Discusses CDC Recent Reports on the Rise of Antimicrobial Resistance

Rhea-AI Summary

FendX Technologies (FDXTF) highlights recent CDC reports on the growing threat of antimicrobial resistance (AR). The CDC report from February 4, 2025, reveals that over 2.8 million antimicrobial-resistant infections occur annually in the U.S., causing at least 1.27 million deaths worldwide. The estimated cost to treat six common AR infections in healthcare settings exceeds US$4.6 billion annually.

The report notably identifies a concerning 5-fold increase in Candida auris cases from 2019 to 2022, with recent surges reported in New York, Georgia, and Florida. The CDC has classified this drug-resistant yeast as an 'urgent threat.'

In response, FendX is developing surface protection products, including their REPELWRAP™ film currently undergoing real-world testing. The company recently signed a letter of intent with US BioSolutions for acquiring IP and establishing a supply agreement for an eco-friendly microbe-trapping sponge.

Positive

• Development of multiple antimicrobial products including REPELWRAP™ film, spray, and catheter coating
• Strategic expansion through letter of intent with US BioSolutions for new microbe-trapping technology
• Addressing a significant market with US$4.6 billion annual treatment costs for AR infections

Negative

• None.

• CDC reports antimicrobial resistance is an urgent global public health threat and, in the U.S., more than 2.8 million antimicrobial resistant infections occur each year¹.

• Antibiotic resistance infections cause at least 1.27 million deaths annually worldwide¹.

Oakville, Ontario--(Newsfile Corp. - April 9, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX") a nanotechnology company developing surface protection products to reduce the spread of pathogens, highlights recent reports from the Centers for Disease Control and Prevention ("CDC") on the facts and stats of antibiotic resistance ("AR") and their continued concern about the emergence and spread of new forms of resistance and rising resistant infections in the community and healthcare.

The CDC report¹, published February 4, 2025, summarizes their facts and stats including national death and infection estimates for several antimicrobial-resistant bacteria and fungi and cites estimated national costs to treat infections caused by six AR germs frequently found in healthcare at more than US$4.6 billion annually. The report also highlights a nearly 5-fold increase in cases of a drug-resistant yeast, Candida auris ("C. auris"), which can cause severe illness, between from 2019 to 2022. Recent news articles report a surge of C. auris infections in New York, Georgia and Florida and reference the CDC declaring this strain of C. auris an "urgent threat"^3,4,5. This is just one example of recent emerging forms of antimicrobial resistance and underscores the growing challenge of AR. The CDC's Antibiotic Resistance Threats Report², published on February 4, 2025, emphasized the need for prevention-focused public health actions, including infection control, accurate laboratory detection, rapid response, appropriate antibiotics and antifungal use, and innovative prevention strategies.

Dr. Carolyn Myers, CEO and President of FendX, states, "These reports of the rise of C. auris underscore the importance of controlling its spread, particularly with the recent rise of infections at various hospitals in the U.S. At FendX, we are dedicated to developing surface protection products, including REPELWRAP™ film, which is currently being tested in real-world studies to confirm it maintains its repelling properties, as well as our other products, including a spray and catheter coating, are in early-stage development." Dr. Myers continues, "We are also focused on business development initiatives to expand our surface protection portfolio. Recently, we signed a letter of intent with US BioSolutions and Scott Smith, to acquire certain intellectual property and to enter into a supply agreement for an eco-friendly sponge designed to attract and trap microbes when combined with a cleaning agent."

About FendX Technologies Inc.

FendX is a Canada-based nanotechnology company focused on developing products to make people's lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners, including McMaster University. The Company has exclusive worldwide licenses to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.

1. Antimicrobial Resistance Facts and Stats | Antimicrobial Resistance | CDC
2. Antimicrobial Resistance Threats in the United States, 2021-2022 | Antimicrobial Resistance | CDC
3. Deadly Superbug Spreading Fast In New York-Experts Are Alarmed
4. https://www.latimes.com/world-nation/story/2025-03-27/deadly-drug-resistant-fungus-cdc-calls-urgent-threat-is-spreading-in-hospitals
5. https://thehill.com/policy/healthcare/5207878-fungus-labeled-urgent-threat-by-cdc-is-spreading-rapidly-hospital-study-finds/

ON BEHALF OF THE COMPANY

"Carolyn Myers"
Carolyn Myers
Chief Executive Officer and Director

Contacts:
Dr. Carolyn Myers, CEO and Director
1-800-344-9868
investor@fendxtech.com

For more information, please visit https://fendxtech.com/ and the Company's profile on SEDAR+ at www.sedarplus.ca.

Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; the Company's goal of developing surface protection products, including REPELWRAP™ film, which is currently being tested in real-world studies to confirm it maintains its repelling properties, as well as our other products, including a spray and catheter coating, are in early-stage development; the Company's focus on business development initiatives to expand its surface protection portfolio; the Company's intention to enter into a supply agreement for an eco-friendly sponge and intention to acquire intellectual property; statements regarding the benefits of the eco-friendly sponge; and products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. These statements are only predictions and involve known and unknown risks which may cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking statements, including: risks that the Company may not complete successful development or commercialization of its film, spray or catheter coating products, including successful completion of real-world testing; risks that the Company may not enter into the supply agreement for the eco-friendly sponge; risks the acquisition of intellectual property may not be completed or receive regulatory approval, if required; adverse market conditions; risks and uncertainties associated with the Company's ability to raise additional capital to complete all of its planned activities; risks related to research and development activities; risks that the Company may not be able to secure any formal manufacturing, distribution or sales agreements related to any of its products; risks that the Company's products, including the eco-friendly sponge, may not be accepted and adopted by the public; the risk that the Company will not obtain necessary approvals and/or clearances for any products as anticipated or at all; the effects of government regulation on the Company's business; risks associated with the Company's ability to obtain and protect rights to its intellectual property; product candidates only being in formulation/reformulation stages; limited operating history; research and development activities; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other factors beyond the Company's control. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company's filings with the British Columbia Securities Commission on SEDAR+ at www.sedarplus.ca.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247851

FAQ

What are the current statistics on antimicrobial resistance according to the CDC's 2025 report?

According to the CDC's February 2025 report, the U.S. experiences over 2.8 million antimicrobial-resistant infections annually, with global deaths reaching 1.27 million. Treatment costs for six common AR infections exceed US$4.6 billion yearly.

How significant is the Candida auris threat mentioned in FDXTF's recent announcement?

CDC data shows a 5-fold increase in Candida auris cases from 2019 to 2022, with recent outbreaks in New York, Georgia, and Florida. The CDC has classified it as an 'urgent threat' due to its drug resistance.

What products is FDXTF developing to address antimicrobial resistance?

FendX is developing REPELWRAP™ film (currently in real-world testing), along with early-stage development of a spray and catheter coating. They're also pursuing acquisition of IP for an eco-friendly microbe-trapping sponge.

What recent business development initiatives has FDXTF announced?

FendX has signed a letter of intent with US BioSolutions to acquire intellectual property and enter a supply agreement for an eco-friendly sponge designed to attract and trap microbes when combined with a cleaning agent.